(4-甲氧基-3-吡啶基)甲醇 | 120277-47-6

• 分子结构分类: 有机化合物 - 有机氧化合物
• 中文名称: (4-甲氧基-3-吡啶基)甲醇
• 英文名称: 3-hydroxymethyl-4-methoxypyridine
• 英文别名: (4-methoxy-pyridin-3-yl)-methanol；(4-methoxypyridin-3-yl)methanol
• CAS: 120277-47-6
• 化学式: C₇H₉NO₂
• mdl: MFCD11100741
• 分子量: 139.154
• InChiKey: OUNUFEHYGMCMEM-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  -0.1
• 重原子数：
  10
• 可旋转键数：
  2
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.285
• 拓扑面积：
  42.4
• 氢给体数：
  1
• 氢受体数：
  3

安全信息

• 危险性防范说明：
  P261,P280,P301+P312,P302+P352,P305+P351+P338
• 危险性描述：
  H302,H315,H320,H335

反应信息

• 作为反应物：
  描述：

  (4-甲氧基-3-吡啶基)甲醇 在 1,3-二甲基-2-咪唑啉酮 、 双(三甲基硫化硅) 、 sodium methylate 作用下， 反应 0.0h， 生成
  参考文献：
  名称：

  3-亚甲基吡啶-4-酮的Diels-Alder反应合成取代的吡喃并[3,2- c ]吡啶

  摘要：

  加热时，二-Boc-吡啶-4-酮衍生物7生成不稳定的3-亚甲基吡啶-4-酮中间体3，将其与活化的烯烃进行Diels-Alder环加成反应，生成取代的吡喃并[3,2- c ]。吡啶的产率中等。

  DOI：

  10.1016/j.tetlet.2005.10.119
• 作为产物：
  描述：

  3-甲基-4-硝基吡啶-N-氧化物 在 盐酸 、 potassium permanganate 、 lithium aluminium tetrahydride 、 三氯化磷 作用下， 以 乙醚 、 氯仿 、 水 为溶剂， 反应 7.66h， 生成 (4-甲氧基-3-吡啶基)甲醇
  参考文献：
  名称：

  Syntheses of Ortho-Hydroxymethylpyridinols and Dioxaphosphorino[m,n-x]pyridines

  摘要：

  Dioxaphosphorino [m,n-x]pyridines compounds have been prepared by condensation of methyl dichlorophosphate with new ortho-hydroxymethylpyridinols.

  DOI：

  10.1080/00397919608004536

文献信息

• Pyrimidine derivatives useful as inhibitors of PKC-theta
  申请人：Barbosa J.M. Antonio

  公开号：US20060025433A1

  公开（公告）日：2006-02-02

  Disclosed are novel compounds of formula (I): wherein X, Y, R 1 , R 2 and R 3 are as defined herein, which are useful as inhibitors of PKC-theta and are thus useful for treating a variety of diseases and disorders that are mediated or sustained through the activity of PKC-theta, including immunological disorders and type II diabetes. This invention also relates to pharmaceutical compositions comprising these compounds, methods of using these compounds in the treatment of various diseases and disorders, processes for preparing these compounds and intermediates useful in these processes.

  披露了公式(I)的新颖化合物：其中X、Y、R1、R2和R3如本文所述定义，它们作为PKC-theta的抑制剂是有用的，因此可用于治疗通过PKC-theta活性介导或维持的多种疾病和失调，包括免疫失调和II型糖尿病。本发明还涉及包含这些化合物的药物组合物、使用这些化合物治疗各种疾病和失调的方法、制备这些化合物的方法以及在这些过程中有用的中间体。
• Process for producing heterocyclic aldehyde
  申请人：Shiomi Yasuhiro

  公开号：US20050124807A1

  公开（公告）日：2005-06-09

  The present invention provides a process for preparing a heterocyclic aldehyde by oxidizing a heterocyclic alcohol with high selectivity and high yield. Specifically, the heterocyclic aldehyde is prepared by reacting a heterocyclic compound having at least one hydroxymethyl group bonded to a carbon atom of a heterocyclic ring with a hypohalogenous acid salt in the presence of a base to oxidize the hydroxymethyl group, wherein reaction is conducted in the co-presence of a 2,2,6,6-tetramethylpiperidine-1-oxyl derivative having at least two 2,2,6,6-tetramethylpiperidine-1-oxyl-4-yl groups.

  本发明提供了一种通过氧化具有高选择性和高产率的杂环醇来制备杂环醛的方法。具体来说，通过将至少有一个羟甲基基团与杂环环的碳原子键合的杂环化合物与次氯酸盐在碱的存在下反应，氧化羟甲基基团来制备杂环醛，其中反应在共存至少具有两个2,2,6,6-四甲基哌啶-1-氧基-4-基团的2,2,6,6-四甲基哌啶-1-氧基-4-基团的2,2,6,6-四甲基哌啶-1-氧基-4-基团的共存下进行。
• Adamantyl Ethanone Pyridyl Derivatives: Potent and Selective Inhibitors of Human 11β-Hydroxysteroid Dehydrogenase Type 1
  作者：Xiangdong Su、Fabienne Pradaux-Caggiano、Nigel Vicker、Mark P. Thomas、Heather Halem、Michael D. Culler、Barry V. L. Potter

  DOI：10.1002/cmdc.201100182

  日期：2011.9.5

  such as type 2 diabetes and obesity. 11β‐Hydroxysteroid dehydrogenase type 1 (11β‐HSD1) catalyses the intracellular conversion of inactive cortisone to cortisol. Selective 11β‐HSD1 inhibitors have shown beneficial effects in various conditions, including diabetes, dyslipidemia and obesity. A series of adamantyl ethanone pyridyl derivatives has been identified, providing potent and selective inhibitors

  活性糖皮质激素水平升高与代谢综合征的几种表型的发展有关，例如 2 型糖尿病和肥胖症。11β-羟基类固醇脱氢酶 1 (11β-HSD1) 催化细胞内无活性的可的松转化为皮质醇。选择性 11β-HSD1 抑制剂已在多种疾病中显示出有益效果，包括糖尿病、血脂异常和肥胖症。已经鉴定了一系列金刚乙酮吡啶基衍生物，提供了有效和选择性的人 11β-HSD1 抑制剂。先导化合物对人和小鼠 11β-HSD1 显示出低纳摩尔抑制，并且对该亚型具有选择性，对 11β-HSD2 和 17β-HSD1 没有活性。构效关系研究表明，未取代的吡啶通过醚或亚砜接头连接到金刚乙酮基序上，为活性提供了合适的药效团。最有效的抑制剂具有 IC50值在 34–48 n M左右对抗人类 11β-HSD1，在人类肝微粒体中表现出合理的代谢稳定性，以及对关键人类 CYP450 酶的弱抑制。
• PYRIMIDINE DERIVATIVES USEFUL AS INHIBITORS OF PKC-THETA
  申请人：BARBOSA Antonio J.M.

  公开号：US20080287410A1

  公开（公告）日：2008-11-20

  Disclosed are novel compounds of formula (I): wherein X, Y, R 1 , R 2 and R 3 are as defined herein, which are useful as inhibitors of PKC-theta and are thus useful for treating a variety of diseases and disorders that are mediated or sustained through the activity of PKC-theta, including immunological disorders and type II diabetes. This invention also relates to pharmaceutical compositions comprising these compounds, methods of using these compounds in the treatment of various diseases and disorders, processes for preparing these compounds and intermediates useful in these processes.

  本发明涉及一种新型化合物，其化学式为（I）：其中X，Y，R1，R2和R3的定义如本文所述，该化合物可用作PKC-theta的抑制剂，因此可用于治疗多种通过PKC-theta的活性介导或维持的疾病和疾病，包括免疫性疾病和2型糖尿病。本发明还涉及包含这些化合物的制药组合物，使用这些化合物治疗各种疾病和疾病的方法，制备这些化合物的过程以及在这些过程中有用的中间体。
• 2,4-DIAMINOPYRIMIDINE COMPOUND
  申请人：Tanaka Akira

  公开号：US20110159019A1

  公开（公告）日：2011-06-30

  Provided is a compound which is useful as an active ingredient for a pharmaceutical having a PKCθ inhibition activity, particularly a pharmaceutical composition for inhibiting acute rejection occurring in transplantation. The present inventors have conducted extensive studies on a compound having a PKCθ inhibition activity, and as a result, they have found that a compound having a structure such as aralkyl and the like on an amino group at the 2-position and also having a structure such as an adamantylalkyl group and the like on an amino group at the 4-position of 2,4-diaminopyrimidine, or a salt thereof has an excellent PKCθ inhibition activity, thereby completing the present invention. The 2,4-diaminopyrimidine compound of the present invention can be used as a PKCθ inhibitor or an inhibitor of acute rejection occurring in transplantation.

  提供了一种化合物，可用作具有PKCθ抑制活性的药物的活性成分，尤其是用于抑制移植中发生的急性排斥的药物组合物。本发明者对具有PKCθ抑制活性的化合物进行了广泛的研究，结果发现，在2-位氨基上具有类似芳基烷基等结构，在4-位氨基上具有类似于金刚烷基烷基等结构的2,4-二氨基嘧啶化合物，或其盐具有出色的PKCθ抑制活性，从而完成了本发明。本发明的2,4-二氨基嘧啶化合物可用作PKCθ抑制剂或用于抑制移植中发生的急性排斥的抑制剂。